SLC5A2 and type 2 diabetes mellitus: In SGLT2 inhibitor CVOTs, the highest representation was in “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE)” at 32.3%, whereas the lowest representation was in “Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes (VERTIS CV)” at 12.6% (40, 48) (Figure 1C).